Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Impact · against what's priced in

Propanc Biopharma (PPCB) is progressing toward a critical value-inflection point by securing a CDMO partner and finalizing the production timeline for its Phase 1b FIH study. The transition from R&D to GMP production readiness for the PRP asset reduces operational risk and provides a clear path to clinical submission in 2026.

PPCB+0.60

No priced-in read yet